FDA Advisers Endorse Controversial Alzheimer’s Drug
The 6-0 vote means Leqembi is one step closer to full approval.

Reuters
Get the Beast Digest newsletter delivered straight to your inbox
By clicking “SIGN UP” you agree to our Terms of Use and Privacy Policy.
An experimental and controversial treatment for Alzheimer’s disease is another step closer to full approval by the Food and Drug Administration. A panel of independent advisers voted 6-0 on Friday that Leqembi can benefit patients, a finding based on clinical trial data that showed it slowed cognitive decline by 27 percent over an 18-month period. However, the drug does not reverse Alzheimer’s and some experts have raised questions about serious side effects and the $25,000-a-year price tag.
Unlock a year of full access to The Daily Beast for $35.
Monthly
$1
First month then $5.99/month
Annual
$35
First year then $59.99/year
Premium
$79
First year then $119.99/year
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.
Looks like you already have a subscription!
- Account (completed)
- Payment (completed)
- Confirmation (completed)
You're all set!
Thanks for subscribing.
- 1Account
- 2Payment
- 3Confirmation
Sign in or create an account
Register below to read this article for free or subscribe
to unlock unlimited access to The Daily Beast.
Monthly
$1
First month then $5.99/month
Annual
$35
First year then $59.99/year
Premium
$79
First year then $119.99/year
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.
Already have an account? Sign In
Looks like you already have a subscription!
- Account (completed)
- Payment (completed)
- Confirmation (completed)
You're all set!
Thanks for subscribing.
- 1Account
- 2Payment
- 3Confirmation